| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $275,500 | 1 | 9 |
Sells | $4,117,337 | 10 | 91 |
| Kaplan Myron | director | 1 | $275,500 | 0 | $0 | $275,500 |
| DUNTON ALAN W | director | 0 | $0 | 1 | $131,300 | $-131,300 |
| Lefkowitz Steven W | director | 0 | $0 | 1 | $475,200 | $-475,200 |
| Todisco Joseph | Chief Executive Officer | 0 | $0 | 1 | $650,000 | $-650,000 |
| Zelnick Kaufman Beth | Chief Legal Officer | 0 | $0 | 1 | $670,264 | $-670,264 |
| Hurlburt Elizabeth | Chief Operating Officer | 0 | $0 | 2 | $711,817 | $-711,817 |
| Dillione Janet | director | 0 | $0 | 4 | $1.48M | $-1.48M |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Over the last 12 months, insiders at CorMedix Inc. have bought $275,500 and sold $4.12M worth of CorMedix Inc. stock.
On average, over the past 5 years, insiders at CorMedix Inc. have bought $171,879 and sold $1.91M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kaplan Myron (director) — $275,500.
The last purchase of 25,000 shares for transaction amount of $275,500 was made by Kaplan Myron (director) on 2025‑10‑23.
| 2025-12-09 | Sale | Lefkowitz Steven W | director | 40,000 0.052% | $11.88 | $475,200 | -0.78% | |
| 2025-12-09 | Sale | Dillione Janet | director | 34,000 0.0446% | $12.00 | $408,000 | -0.78% | |
| 2025-12-02 | Sale | Dillione Janet | director | 46,657 0.0605% | $10.00 | $466,570 | +15.40% | |
| 2025-11-24 | Sale | Dillione Janet | director | 26,343 0.0343% | $9.93 | $261,586 | +6.26% | |
| 2025-11-14 | Sale | Dillione Janet | director | 30,000 0.039% | $11.42 | $342,600 | -7.57% | |
| 2025-10-23 | Kaplan Myron | director | 25,000 0.0326% | $11.02 | $275,500 | -2.65% | ||
| 2025-09-12 | Sale | Todisco Joseph | Chief Executive Officer | 50,000 0.0673% | $13.00 | $650,000 | -14.06% | |
| 2025-09-12 | Sale | DUNTON ALAN W | director | 10,000 0.0136% | $13.13 | $131,300 | -14.06% | |
| 2025-09-11 | Sale | Hurlburt Elizabeth | Chief Operating Officer | 41,121 0.055% | $13.08 | $537,863 | -15.01% | |
| 2025-09-09 | Sale | Zelnick Kaufman Beth | Chief Legal Officer | 50,000 0.0689% | $13.41 | $670,264 | -14.54% | |
| 2025-09-09 | Sale | Hurlburt Elizabeth | Chief Operating Officer | 12,876 0.0179% | $13.51 | $173,955 | -14.54% | |
| 2024-11-14 | Sale | Hurlburt Elizabeth | EVP | 140,027 0.2312% | $11.18 | $1.57M | +1.09% | |
| 2024-10-31 | Mistry Erin | EVP, Chief Commercial Officer | 1,500 0.0026% | $9.99 | $14,985 | +10.39% | ||
| 2024-03-13 | Todisco Joseph | Chief Executive Officer | 13,561 0.024% | $3.74 | $50,718 | +76.54% | ||
| 2023-12-15 | DUNTON ALAN W | director | 3,000 0.0055% | $3.30 | $9,900 | +52.11% | ||
| 2023-12-14 | DUNTON ALAN W | director | 3,000 0.0055% | $3.45 | $10,350 | +45.51% | ||
| 2023-11-17 | Mistry Erin | Chief Commercial Officer | 1,000 0.0018% | $4.00 | $4,000 | +17.46% | ||
| 2023-09-08 | Todisco Joseph | Chief Executive Officer | 10,000 0.0183% | $3.71 | $37,100 | +4.05% | ||
| 2023-05-18 | Kaplan Myron | director | 6,000 0.0139% | $4.54 | $27,258 | -14.19% | ||
| 2023-05-17 | Todisco Joseph | Chief Executive Officer | 5,000 0.0119% | $4.58 | $22,900 | -12.90% |
| Todisco Joseph | Chief Executive Officer | 509496 0.6467% | $5.78M | 6 | 1 | +16.79% |
| Kaplan Myron | director | 201034 0.2552% | $2.28M | 18 | 0 | +9.53% |
| Zelnick Kaufman Beth | Chief Legal Officer | 180418 0.229% | $2.05M | 0 | 1 | |
| Hurlburt Elizabeth | Chief Operating Officer | 176990 0.2246% | $2.01M | 0 | 4 | |
| Lefkowitz Steven W | director | 80498 0.1022% | $912,847.32 | 7 | 7 | +58.05% |
| Dillione Janet | director | 48473 0.0615% | $549,683.82 | 9 | 4 | <0.0001% |
| DUNTON ALAN W | director | 40250 0.0511% | $456,435.00 | 4 | 1 | +43.21% |
| Gelbfish Gary A. | director | 2101121 2.6668% | $23.83M | 2 | 0 | <0.0001% |
| PHARMABIO DEVELOPMENT INC | 10 percent owner | 778563 0.9882% | $8.83M | 0 | 1 | |
| TELLEZ CORA M | director | 182371 0.2315% | $2.07M | 15 | 0 | <0.0001% |
| Khan Mehmood | director | 178767 0.2269% | $2.03M | 10 | 0 | +14.81% |
| ELLISON RUSSELL H | director | 160000 0.2031% | $1.81M | 1 | 0 | |
| ARMSTRONG JR. JOHN L. | Exec VP of Tech Operations | 96878 0.123% | $1.1M | 5 | 0 | +5.98% |
| Baluch Khoso | Chief Executive Officer | 60905 0.0773% | $690,662.70 | 9 | 0 | +19.59% |
| MILBY RANDY | Chief Executive Officer | 57026 0.0724% | $646,674.84 | 20 | 0 | +32.67% |
| Houser Mark T. | Chief Medical Officer | 52832 0.0671% | $599,114.88 | 2 | 0 | |
| Mistry Erin | EVP, Chief Commercial Officer | 52011 0.066% | $589,804.74 | 2 | 0 | +13.92% |
| Lefkowitz James | director | 40272 0.0511% | $456,684.48 | 1 | 0 | |
| Markvicka Taunia | director | 37100 0.0471% | $420,714.00 | 3 | 0 | <0.0001% |
| Duffy Matthew | director | 28571 0.0363% | $323,995.14 | 0 | 2 | |
| Cook Robert W. | Chief Financial Officer | 27517 0.0349% | $312,042.78 | 6 | 0 | <0.0001% |
| Houghton John C. | President and CEO | 17328 0.022% | $196,499.52 | 2 | 0 | |
| LENZ BRIAN | CFO, TREASURER & SECRETARY | 17000 0.0216% | $192,780.00 | 3 | 0 | |
| Stewart Robert A | director | 11000 0.014% | $124,740.00 | 1 | 0 | <0.0001% |
| GEORGE MICHAEL W | director | 10000 0.0127% | $113,400.00 | 3 | 0 | <0.0001% |
| Costa Paulo F | director | 10000 0.0127% | $113,400.00 | 1 | 0 | <0.0001% |
| HOFER TIMOTHY M | director | 8425 0.0107% | $95,539.50 | 1 | 0 | |
| Mounts Phoebe | General Counsel | 7200 0.0091% | $81,648.00 | 3 | 0 | +69.23% |
| David Matthew T | Interim CEO and CFO | 3150 0.004% | $35,721.00 | 3 | 0 | +83.5% |
| Pfaffle Antony | Chief Scientific Officer | 0 0% | $0 | 1 | 19 |
CorMedix Inc. (CRMD) | $3,611,891 | 113 | 13.40% | $893.47M |
$94,912,877 | 34 | -7.15% | $854.23M | |
$24,857,912 | 21 | -35.40% | $779.96M | |
$3,556,951 | 18 | 9.64% | $858.31M | |
$26,254,270 | 14 | 24.18% | $900.46M | |
$7,254,955 | 14 | 20.70% | $759M | |
$133,809,976 | 13 | 31.29% | $896.44M | |
$103,194,328 | 13 | 9.02% | $849.64M | |
$92,357,691 | 12 | 87.24% | $860.23M | |
$278,247,340 | 12 | 58.08% | $935.54M | |
$11,541,901 | 10 | 8.07% | $918.03M | |
$117,959,652 | 9 | -12.47% | $911M | |
$160,798,946 | 8 | -3.92% | $910.02M | |
$49,165,200 | 7 | 12.92% | $780.87M | |
$1,229,547 | 7 | 11.98% | $849.01M | |
$51,588,185 | 5 | 19.18% | $738.68M | |
$19,420,853 | 5 | 4.35% | $897.93M | |
$45,070 | 4 | 10.31% | $912.68M | |
$13,900 | 1 | -39.25% | $952.27M |
| Increased Positions | 144 | +101.41% | 15M | +44.17% |
| Decreased Positions | 60 | -42.25% | 6M | -18.29% |
| New Positions | 51 | New | 7M | New |
| Sold Out Positions | 32 | Sold Out | 4M | Sold Out |
| Total Postitions | 226 | +59.15% | 43M | +25.88% |
| Blackrock, Inc. | $65,359.00 | 7.2% | 5.69M | +328,474 | +6.13% | 2025-09-30 |
| Vanguard Group Inc | $45,703.00 | 5.04% | 3.98M | -347,887 | -8.04% | 2025-09-30 |
| Marshall Wace, Llp | $39,910.00 | 4.4% | 3.47M | +893,518 | +34.63% | 2025-09-30 |
| Deerfield Management Company, L.P. | $38,191.00 | 4.21% | 3.32M | +3M | New | 2025-09-30 |
| State Street Corp | $21,091.00 | 2.32% | 1.84M | +233,973 | +14.61% | 2025-09-30 |
| Geode Capital Management, Llc | $20,794.00 | 2.29% | 1.81M | +213,450 | +13.37% | 2025-09-30 |
| Citadel Advisors Llc | $19,729.00 | 2.17% | 1.72M | +2,872 | +0.17% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $14,512.00 | 1.6% | 1.26M | +512,979 | +68.4% | 2025-09-30 |
| Ubs Group Ag | $12,535.00 | 1.38% | 1.09M | +814,964 | +295.34% | 2025-09-30 |
| Morgan Stanley | $9,693.00 | 1.07% | 843,571 | +76,318 | +9.95% | 2025-09-30 |